| Identification | Back Directory | [Name]
procyclidine | [CAS]
77-37-2 | [Synonyms]
Vagosin
Kemadrine
Tricyclamol
procyclidine
α-Cyclohexyl-α-phenyl-1-pyrrolidine-1-propanol
1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol | [EINECS(EC#)]
201-023-0 | [Molecular Formula]
C19H29NO | [MDL Number]
MFCD00057231 | [MOL File]
77-37-2.mol | [Molecular Weight]
287.44 |
| Chemical Properties | Back Directory | [Melting point ]
85.5-86.5° | [Boiling point ]
429.73°C (rough estimate) | [density ]
0.9954 (rough estimate) | [refractive index ]
1.5180 (estimate) | [pka]
14.21±0.29(Predicted) | [Water Solubility ]
1.055mg/L(22.5 ºC) |
| Hazard Information | Back Directory | [Definition]
ChEBI: A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3. | [Uses]
Antiparkinsonian; relaxant (skeletal
muscle). | [Brand name]
Kemadrin (Monarch). | [Synthesis]
Procyclidine, 1-cyclohexyl-1-phenyl-3-pirrolidinopropan-1-ol (10.2.3), is
synthesized in the exact same manner, except beginning with 2-(1-pyrrolidino) propiophenone [28–32]. | [in vivo]
Procyclidine (subcutaneous injection, 0.3-6.0 mg/kg) in combination with physostigmine (PhS) increases protection in a dose-dependent manner in rats and guinea pigs infected with soman and can prevent seizures altogether[1].
| Animal Model: | Male Sprague-Dawley rats, Dunkin-Hartley male guinea pigs[1] | | Dosage: | 0.3-6.0 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Increased protection, resulting in 1.92, 2.24, 3.95 and 5.07 fold in rats, 3.00, 3.25, 4.50 and 4.70 fold in guinea pigs at the doses of 0.3, 1.0, 3.0 or 6.0 mg/kg, respectively.
Protected the neurological integrity of the brain and prevented Soman-induced severe brain damage in the hippocampus, cortex, amygdala and thalamus.
|
| [IC 50]
NMDA Receptor |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|